Physician profile
Cassie Mcgee
NPI 1992165104
$9,973.42
in general payments reported to CMS, 2019-2025
34 companies · $1,597 in 2025
The $1,597 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,611 · 2022: $1,732 · 2023: $2,532 · 2024: $2,502 · 2025: $1,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,523 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,522.99 |
| Education | $107.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,934.27 | 2021-2025 | |
| Janssen Biotech, INC. | $828.03 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $590.95 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $574.11 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $515.98 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $460.92 | 2022-2024 | Dupixent |
| Amgen INC. | $408.07 | 2022-2025 | Otezla, Otezla |
| Gilead Sciences, INC. | $398.02 | 2021-2022 | |
| Lilly USA, LLC | $247.35 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $232.30 | 2022-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $211.81 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $181.39 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $161.95 | 2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.57 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $119.74 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $119.40 | 2021 | |
| Incyte Corporation | $118.75 | 2022-2024 | Opzelura |
| Takeda Pharmaceuticals U.S.A., INC. | $108.85 | 2021-2022 | |
| Pfizer INC. | $85.58 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $77.27 | 2022-2023 | Ilumya |
| Daiichi Sankyo INC. | $63.23 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $61.75 | 2021 | |
| Mylan Specialty L.P. | $45.25 | 2021 | |
| Merck Sharp & Dohme LLC | $37.81 | 2021 | |
| Arcutis Biotherapeutics, INC. | $37.80 | 2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $32.43 | 2022 | |
| Galderma Laboratories, L.P. | $31.77 | 2022-2025 | Nemluvio |
| Redhill Biopharma INC. | $28.30 | 2022 | |
| Amarin Pharma, INC. | $25.82 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.18 | 2022 | |
| Glaxosmithkline, LLC. | $17.83 | 2021 | |
| Eisai INC. | $16.77 | 2021 | |
| Dermavant Sciences, INC. | $14.98 | 2023 | Vtama |
| Currax Pharmaceuticals LLC | $14.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassie Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.